Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
4
67%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Recruiting2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

withdrawn117%
active_not_recruiting117%
completed233%
recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
withdrawnphase_2

Pilot Study on Trametinib for Surgical Unruptured AVMs

NCT06098872
completedphase_2

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

NCT04258046
active_not_recruitingphase_1

Trametinib Treatment for Complicated Vascular Anomalies

NCT07072403
recruitingphase_2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

NCT06739395
recruitingphase_2

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

NCT06555237
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06098872Phase 2

Pilot Study on Trametinib for Surgical Unruptured AVMs

Withdrawn
NCT04258046Phase 2

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Completed
NCT07072403Phase 1

Trametinib Treatment for Complicated Vascular Anomalies

Active Not Recruiting
NCT06739395Phase 2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting
NCT06555237Phase 2

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

Recruiting
NCT01647659Phase 1

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6